scorecardresearch
Add as a preferred source on Google
Thursday, April 16, 2026
TopicIndia pharma industry

Topic: india pharma industry

Customs waiver on petrochemicals to cost 1,800 cr in lost revenue; govt admits impact on other sectors

The war in West Asia has led to supply chain disruptions, payment delays, increased freight costs, and longer transit times, impacting trade.

Drug regulator calls on Indian pharma to move beyond generics, address dependence on bulk imports

Advice comes at a time when India accounts for a 5th of global generic drug supply & 40% of generics used in US. However, this strength in finished formulations relies on imported ingredients.

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.

Why Trump’s executive order lowering prescription drug prices won’t rattle Indian pharma industry

The order aims to slash drug prices by up to 80%. Indian industry had been on edge since March amid threats of reciprocal tariff on pharmaceutical products.

How reciprocal Trump tariffs may impact Indian pharma, and become a bitter pill for the US

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, with chunk of their earnings hinging on exports to the country.

Hyderabad will be India’s life sciences capital, says CM Reddy as BioAsia 2025 kicks off

Telangana CM says his government will create 'pharma villages', potentially creating over 5 lakh jobs, and is also considering a dedicated life sciences policy.

24 mega-seller drugs set to lose patents in US, big opportunity for Indian drugmakers — govt report

Patent expiry would mean that drugmakers will be able to launch generic versions of the blockbuster drugs, which are typically priced up to 90 percent lower than their innovator drug.

No conferences in foreign locales, no gifts or hospitality — govt’s new marketing code for drugmakers

Uniform Code for Pharmaceutical Marketing Practices 2024, which replaces a 2015 code, remains voluntary, with its implementation watched by ethics panel constituted by pharma associations.

‘Can hamper entry of new drugs’ — groups raise alarm over IP proposals part of India-EFTA talks

India & EFTA (Iceland, Liechtenstein, Norway and Switzerland) are negotiating Trade and Economic Partnership Agreement (TEPA) that is likely to be finalized within next few weeks.

‘Adulterated drugs’ to breakthrough cancer therapy — how India’s health & pharma sector fared in 2023

The year was eventful with National Medical Commission's flip-flops over controversial decisions, tightening of various norms and launch of made-in-India drugs to treat rare diseases.

On Camera

The Delimitation Dilemma—What Southern politicians should be bargaining for

Instead of fighting the inevitable population shift, southern leaders should seek to integrate migrants and preserve their local influence.

Indian LNG importers accelerate spot market purchases as prices dip

The purchases mark a turnaround after Indian buyers had earlier limited spot buying and canceled tenders because offers were too expensive.

Why Siliguri Corridor is strategically important for India & how it is being secured | Cut The Clutter

This special edition of Cut The Clutter, straight from the Siliguri corridor, details the strategic importance of the narrow strip of land in West Bengal, and how it’s a vital link connecting the Northeast to the rest of India.

The world’s in a flux. India must reform, consolidate & build a strong economy

We now live in a world order that will keep shifting. India must use this window. This also means we remain disciplined enough not to be knee-jerked into reacting to what Pakistan sees as its moment in the sun.